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Sir,
As of April 5, 2020, >120,000 cases of coronavirus dis-ease 2019 (COVID-19) and 15,362 deaths have been 
reported in Italy.
The median age of patients is between 49 and 56 
years.1–3 The incubation period of this virus has been 
reported to be 5.2 days,4 although there is suggestion that 
it may be as long as 14 days. The clinical syndrome is non-
specific, which makes it clinically indistinguishable from 
other viral respiratory illnesses. Some patients may even 
be asymptomatic.5
Due to low specificity, laboratory tests may not be use-
ful in establishing the diagnosis of COVID-19; however, 
they can help appraise the clinical condition of a patient 
and may be indicative of COVID-19, resulting in further 
testing with polymerase chain reaction and radiologic 
studies.6 Some laboratory findings have been related 
to severe 2019 novel coronavirus pneumonia and may 
require admission to intensive care unit or mechanical 
ventilation or may lead to death. These findings include 
higher body temperature, leukocytosis, accompanied by 
an increase in neutrophil count and neutrophil percent-
age, and decrease in lymphocyte count and lymphocyte 
percentage. Lymphopenia was more severe and common 
in patients with severe 2019 novel coronavirus pneumo-
nia,6 and it was probably caused by the translocation of 
lymphocyte from peripheral blood to lungs.4 An increase 
in d-dimer level was also found, which reflected a hyper-
coagulable state that might promote pulmonary micro-
thrombosis, increased α-hydroxybutyrate dehydrogenase 
activity, lactate dehydrogenase activity, and creatine kinase 
activity, which were usually used to evaluate the degree of 
myocardial injury.
Although most cases seem to be mild, all patients 
admitted to the hospital have pneumonia with infiltrates 
on chest x-ray and ground glass opacities on chest com-
puted tomography.6
The knowledge of symptoms, laboratory findings, 
and imaging aspects is of paramount importance for all 
physicians, including ones from diverse backgrounds as 
surgeons, who are called to face COVID-19 disease in their 
daily practice as well. As far as the plastic and reconstruc-
tive surgery field is concerned, to date, no certain direct 
impact of COVID-19 on body soft tissues, including mam-
mary, has been reported. However, plastic and reconstruc-
tive surgeons can be involved in the evaluation of patients 
presenting with fever without other symptoms of COVID-
19, in their postoperatory period. The background of 
fever due to breast oncologic surgery and other systemic 
symptoms may initially overlap the ones typical of COVID-
19; an immediate differentiation could prompt the treat-
ment and avoid the shortcoming of a missed or delayed 
COVID-19 diagnosis.
In this regard, plastic and reconstructive surgery, like 
any other surgery, represents an important stress for our 
body, which responds by releasing chemical mediators 
that cause generalized inflammation. Some of these are 
responsible for a slight increase in temperature; there-
fore, a fever of 37.3°C–37.4°C in the first postoperative 
days is a paraphysiologic condition that does not require 
any type of treatment, but only monitoring.
Moreover, in breast surgery, there are other causes 
of fever, due to complications of the oncologic resection 
or of the reconstructive procedure. In the first days after 
the surgery, a clinical picture characterized by fever, 
swelling, hot and flushed breast skin can occur. In this 
case, a clinical and an US evaluation is important to find 
the eventual presence of a blood or fluid collection. 
If there is a suspicion of a hematoma, which is usually 
accompanied by a decrease in hemoglobin levels, the 
collection must be drained. On the other hand, if there 
is the suspicion of a seroma, it is necessary to aspirate 
the liquid and analyze it. If the seroma does not resolve 
with the aspiration and antibiotic therapy, it must be 
removed by surgery.
Laboratory findings may be the driver of the diagnos-
tic workup in this setting. As described previously, lym-
phopenia (70%), prolonged prothrombin time (58%), 
and elevated lactate dehydrogenase (40%) may be indica-
tive of COVID-19, although they are not specific. On the 
other side, in patients undergoing breast surgery, these 
laboratory findings are not altered or are not investigated 
because the diagnosis is mainly clinical. However, it is 
always important to perform an evaluation of the hemo-
globin levels in case of suspected hematoma and a labora-
tory analysis of the aspirate in case of suspected seroma.
In conclusion, the possible overlap of COVID-19 
clinical syndrome with different postsurgical conditions 
should be recognized and deserves a proper investigation 
since the very beginning of case presentation. The rapid 
diagnosis and isolation of COVID-19 cases—recognized to 
be public health interventions slowing the spread7—rely 
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on the prompt preparation and knowledge of all physi-
cians to confront this unprecedented pandemic.
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